PROPHYLAXIS OF OPPORTUNISTIC INFECTIONS

Aberg, 1998, Eradication of disseminated Mycobacterium avium complex after twelve months anti-mycobacterial therapy and response to highly active antiretroviral therapy, J Infect Dis, 178, 1446, 10.1086/314469 Benson, 2000, Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial, J Infect Dis, 181, 1289, 10.1086/315380 Bozzette, 1995, A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection, N Engl J Med, 332, 693, 10.1056/NEJM199503163321101 Bozzette, 1991, A controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome, N Engl J Med, 324, 580, 10.1056/NEJM199102283240902 Brosgart, 1998, A randomized, placebo controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals, AIDS, 12, 269, 10.1097/00002030-199803000-00004 Carr, 1998, Treatment of HIV-1 associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy, Lancet, 351, 256, 10.1016/S0140-6736(97)07529-6 Carr, 1992, Low-dose trimethoprim–sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS, Ann Intern Med, 117, 106, 10.7326/0003-4819-117-2-106 Casado, 1999, Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy, AIDS, 13, 1497, 10.1097/00002030-199908200-00009 1998, Centers of Disease Control and Prevention (CDC): Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: Principles of therapy and revised recommendations, MMWR Morb Mortal Wkly Rep, 47, 1 Chan, 1999, Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides, J Infect Dis, 180, 369, 10.1086/314893 Clifford, 1999, HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy, Neurology, 52, 623, 10.1212/WNL.52.3.623 Currier JS, Williams PL, Koletar S, et al: Discontinuation of Mycobacterium avium complex (MAC) prophylaxis for subjects with antiretroviral therapy induced CD4 increases: A randomized, double-blind, placebo-controlled trial. Ann Intern Med, in press Dannemann, 1992, Treatment of toxoplasmic encephalitis in patients with AIDS: A randomized trial compared pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine, Ann Intern Med, 116, 33, 10.7326/0003-4819-116-1-33 El-Sadr, 1999, A randomized trial of daily and thrice weekly trimethoprim–sulfamethoxazole for the prevention of Pneumocystis carinii pneumonis in HIV infected individual, Clin Infect Dis,, 29, 783, 10.1086/520433 El-Sadr, 1998, Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both, N Engl J Med, 339, 1889, 10.1056/NEJM199812243392604 El-Sadr WM, Eberly L, Cohn D: Mortality associated with the occurrence of HIV-related opportunistic disease (ODs) prior to and since HAART [abstract 1157]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September, 1999 El-Sadr, 2000, Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy, N Engl J Med, 342, 1085, 10.1056/NEJM200004133421503 Ena, 1994, Once-a-month administration of intravenous pentamidine to patients infected with human immunodeficiency virus as prophylaxis for Pneumocystis carinii pneumonia, Clin Infect Dis, 18, 901, 10.1093/clinids/18.6.901 Furrer, 1999, Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infected adults treated with combination antiretroviral therapy, N Engl J Med, 340, 1301, 10.1056/NEJM199904293401701 Galgiani JN, Cloud GA, Catanzaro A, et al: Fluconazole (FLU) vs. itraconazole (ITRA) for coccidioidomycosis: Randomized, multicenter, double-blinded trial in nonmeningeal progressive infections [abstract 100]. 36th Annual Meeting of the Infectious Diseases Society of America. Denver, November, 1998 Gallant, 1992, Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine, J Infect Dis, 166, 1223, 10.1093/infdis/166.6.1223 Gordon, 2000, Rifampin and pyrazinamide versus isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial, JAMA, 283, 1445, 10.1001/jama.283.11.1445 Greenberg, 1993, Trimethoprim–sulfamethoxazole induces reversible hyperkalemia, Ann Intern Med, 119, 291, 10.7326/0003-4819-119-4-199308150-00007 Halsey, 1998, Randomised trial of isoniazid versus rifampin and pyrazinamide for prevention of tuberculosis in HIV-1 infection, Lancet, 351, 786, 10.1016/S0140-6736(97)06532-X Havlir, 1996, Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both, N Engl J Med, 335, 392, 10.1056/NEJM199608083350604 Havlir, 1998, Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS, Clin Infect Dis, 27, 1369, 10.1086/515018 Helweg-Larsen, 1999, Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia, Lancet, 354, 1347, 10.1016/S0140-6736(99)03320-6 Hoover, 1993, Clinical manifestations of AIDS in the era of pneumocystis prophylaxis, N Engl J Med, 329, 1922, 10.1056/NEJM199312233292604 Jabs, 1998, Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy, Am J Ophthalmol, 126, 817, 10.1016/S0002-9394(98)00285-2 Jacobson, 1997, Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy, Lancet, 349, 1443, 10.1016/S0140-6736(96)11431-8 Jung, 1994, Management of adverse reactions to trimethroprim-sulfamethoxazole in human immunodeficiency virus-infected patients, Arch Intern Med, 154, 2402, 10.1001/archinte.154.21.2402 Katlama, 1996, Pyrimethamine–clindamycin vs. pyrimethamine–sulfadiazine as acute and long-term for toxoplasmic encephalitis in patients with AIDS, Clin Infect Dis, 22, 268, 10.1093/clinids/22.2.268 Kaufmann, 1998, CD4-cell count in HIV-1-infected individuals remaining viremic after highly active antiretroviral therapy: Swiss HIV Cohort Study, Lancet, 351, 723, 10.1016/S0140-6736(98)24010-4 Leoung G, Stanford J, Giordano M, et al: A randomized, double blind trial of TMP–SMX dose escalation vs. direct challenge in HIV+ persons at risk of PCP and with prior treatment-limiting rash or fever [abstract LB10]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September, 1997 Lopez JC, Miro JM, Pena JM, et al: Discontinuation of PCP prophylaxis is safe in HIV-infected patients after immunological recovery with HAART. Results of the Gesida 04/98 Study [abstract LB-24]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, September, 1999 Lyles, 1999, Prognostic value of plasma HIV RNA in the natural history of Pneumocystis carinii pneumonia, cytomegalovirus and Mycobacterium avium complex. Multicenter AIDS Cohort Study, AIDS, 13, 341, 10.1097/00002030-199902250-00006 MacDonald, 1998, Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevation in CD4 T cells in response to highly active antiretroviral therapy, J Infect Dis, 177, 1182, 10.1086/515281 Martin, 1993, A severe systemic reaction to trimethoprim–sulfamethoxazole in a patient infected with the human deficiency virus, Clin Infect Dis, 16, 175, 10.1093/clinids/16.1.175-b 1989, Masur H (Chairman): Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with HIV, MMWR Morb Mortal Wkly Rep, 38, 1 Masur, 1992, Drug therapy: Prevention and treatment of pneumocystis pneumonia, N Engl J Med, 327, 1853, 10.1056/NEJM199212243272606 Masur, 1993, Recommendations on prophylaxis and therapy for disseminated mycobacterium avium complex disease in patients infected with the human immunodeficiency virus, N Engl J Med, 329, 898, 10.1056/NEJM199309163291228 McElrath J, Malhotra U, Musey L, et al: Improved cellular immunity in acute HIV-1 infection following antiretroviral therapy [abstract 31177]. 12th World AIDS Conference. Geneva, Switzerland, 1998 McKinsey, 1999, Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: Randomized, placebo controlled, double-blind study, Clin Infect Dis, 28, 1049, 10.1086/514744 Michelet C, Arvieux C, Aubert V, et al: Viral ocular involvement after initiation of antiprotease inhibitor therapy [abstract 315]. 4th Conference on Retroviruses and Opportunistic Infections. Washington, January, 1997 Michelet, 1998, Opportunistic infections occurring during highly active antiretroviral treatment, AIDS, 12, 1815, 10.1097/00002030-199814000-00013 Mwinga, 1998, Twice weekly tuberculosis preventive therapy in HIV infection in Zambia, AIDS, 12, 2457, 10.1097/00002030-199818000-00014 Narita, 1998, Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS, Am J Respir Crit Care Med, 158, 157, 10.1164/ajrccm.158.1.9712001 Nightingale, 1993, Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infections in AIDS, N Engl J Med, 329, 828, 10.1056/NEJM199309163291202 Opravil, 1995, Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients, Clin Infect Dis, 20, 531, 10.1093/clinids/20.3.531 Pallela, 1998, Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection, N Engl J Med, 338, 853, 10.1056/NEJM199803263381301 Para MF, Dohn M, Frame P, et al: Gradual initiation of trimethoprim/sulfamethoxazole (T/S) as primary prophylaxis for Pneumocystis carinii pneumonia (PCP) [abstract 2]. 4th Conference on Retroviruses and Opportunistic Infections. Washington, January, 1997 Phair, 1990, The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type I, N Engl J Med, 322, 161, 10.1056/NEJM199001183220304 Pierce, 1996, A randomized trial of clarithromycin as prophylaxis against Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome, N Engl J Med, 335, 384, 10.1056/NEJM199608083350603 Podzamczer, 1995, Intermittent trimethoprim–sulfamethoxazole compared with dapsone–pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmic encephalitis in patients infected with HIV, Ann Intern Med, 122, 755, 10.7326/0003-4819-122-10-199505150-00004 Powderly, 1998, Recovery of the immune system with antiretroviral therapy, The end of opportunism? JAMA, 280, 72, 10.1001/jama.280.1.72 Powderly, 1995, A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection, N Engl J Med, 332, 700, 10.1056/NEJM199503163321102 Powderly, 1992, A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome, N Engl J Med, 326, 793, 10.1056/NEJM199203193261203 Powderly, 1999, The interaction of opportunistic infections and HIV replication, AIDS, 13, 1603, 10.1097/00002030-199909100-00001 Race, 1998, Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease, Lancet, 351, 252, 10.1016/S0140-6736(97)04352-3 Ravaux I, Quinson AM, Chadapaud S, et al: Discontinue primary and secondary prophylaxis regimens in selected HIV-infected patients treated with HAART [abstract I-203]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, September, 1998 1998, Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, Ann Intern Med, 128, 1100 Rosenberg, 1997, Vigorous HIV-1-specific CD4+ T cell responses associated with the control of viremia, Science, 278, 1447, 10.1126/science.278.5342.1447 Saag, 1999, A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis, Clin Infect Dis, 28, 291, 10.1086/515110 Saah, 1995, Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. Multicenter AIDS Cohort Study, JAMA, 273, 1197, 10.1001/jama.273.15.1197 Sattler, 1988, Trimethoprim–sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: A prospective, noncrossover study, Ann Intern Med, 109, 280, 10.7326/0003-4819-109-4-280 Schneider, 1992, A controlled trial of aerosolized pentamidine or trimethomrim–sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus, N Engl J Med, 327, 1836, 10.1056/NEJM199212243272603 Schneider, 1995, Efficacy and toxicity of two doses of trimethoprim–sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus, J Infect Dis, 171, 1632, 10.1093/infdis/171.6.1632 Schneider, 1999, Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy, Lancet, 353, 210, 10.1016/S0140-6736(98)07204-3 Schuman, 1997, Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection: A randomized, double blind, placebo-controlled trial, Ann Intern Med, 126, 689, 10.7326/0003-4819-126-9-199705010-00003 Sepkowitz, 1998, Effect of HAART on natural history of AIDS-related opportunistic disorders, Lancet, 351, 228, 10.1016/S0140-6736(05)78279-9 Spector, 1996, Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS, N Engl J Med, 334, 1491, 10.1056/NEJM199606063342302 Spector, 1998, Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients, J Clin Invest, 101, 497, 10.1172/JCI1101 Spector, 1999, Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS, J Virology, 73, 7027, 10.1128/JVI.73.8.7027-7030.1999 Supparatpinyo, 1998, A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients with the human immunodeficiency virus, N Engl J Med, 339, 1739, 10.1056/NEJM199812103392403 Teofilo, 1998, Progressive multifocal leukoencephalopathy regression with highly active antiretroviral therapy, AIDS, 12, 449 Tortajada C, Martinez E, Miro JM, et al: Withdrawal of primary prophylaxis against P. carinii and T. gondii in adult HIV-1 infected individuals with stable CD4 cell count above 200/μl [abstract 22179]. 12th World AIDS Conference. Geneva, Switzerland, 1998 Tural, 1998, Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients, J Infect Dis, 177, 1080, 10.1086/517399 1999, USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus, MMWR Morb Mortal Wkly Rep, 48, 1 Vrabec, 1998, Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts, Ophthalmology, 105, 1259, 10.1016/S0161-6420(98)97031-2 Weverling, 1999, Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection, Lancet, 353, 1293, 10.1016/S0140-6736(99)03287-0 Wheat, 1993, Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome, Ann Intern Med, 118, 610, 10.7326/0003-4819-118-8-199304150-00006 Williams, 1999, Joint effects of HIV-1 RNA levels and CD4+ lymphocyte cells on the risk of specific opportunistic infections, AIDS, 13, 1035, 10.1097/00002030-199906180-00006